亚宝药业(600351.SH)终止SY-009的临床研究开发工作

Core Viewpoint - The company has decided to terminate the clinical research and development of the SY-009 project after a careful evaluation of various factors, including project progress, investment risks, and future market value [1] Group 1: Project Termination - The company will focus its research resources on more advantageous projects within its pipeline [1] - The decision to terminate SY-009 will lead to a full impairment provision for the capitalized R&D amount of the project [1] Group 2: Financial Impact - The impairment provision will reduce the company's total profit for the year 2025 by 55.7933 million yuan [1] - The financial data mentioned is unaudited, and the final accounting treatment will be confirmed in the company's 2025 annual report [1]